Live
- Sensex, Nifty slip under pressure amid weak global cues
- Posters on novel solutions to problems at Tech Summit
- Conduct Tiruchanoor fest akin to Tirumala’s: TTD EO
- Allocate Khelo India funds for sports infra in SVU
- BJP stages protests in various dists over alleged Waqf encroachments
- CM defends BPL ration card cancellation
- Industry should make use of Rs 1-trn ANRF fund: Goyal
- TTD chairman meets Telangana CM
- MITS faculty awarded with PhD by VTU
- Sannapureddy takes charge as RTC regional chairman
India to test Ayurvedic pills for corona treatment
India is working on four formulations of traditional medicine to treat the novel coronavirus or COVID-19 infection and the trials will start within one week, the Minister of AYUSH said on Thursday.
New Delhi: India is working on four formulations of traditional medicine to treat the novel coronavirus or COVID-19 infection and the trials will start within one week, the Minister of AYUSH said on Thursday.
Shripad Y Naik, the Union minister of AYUSH (ayurveda, yoga, unani, siddha and homeopathy), tweeted saying that the ministry is working with the Council of Scientific & Industrial Research (CSIR) to validate four Ayush formulations to treat COVID-19 and these will be tried as "add-on therapy and standard care" for patients infected with the virus.
"I am sure and quite hopefull that, our traditional medicinal system will show the way to overcome this pandemics," Naik said in another tweet.
On Wednesday, AYUSH secretary Vaidya Rajesh Kotecha told news agency ANI that the AYUSH and CSIR collaboration has a larger perspective. "This is once in a lifetime opportunity. This type of study never happened in our country. These four candidates are -- Ashwagandha, Yashtimadhu (Mulethi), Guduchi + Pippali (Giloy) and AYUSH-64, which was invented for the treatment of malaria and its repurposing is going on," he said and added that result will come within three months.
Earlier on May 7, CSIR Director-General Shekhar Mande had said, "There has been a long-felt need for many of the Ayurvedic formulations. We should actually try from modern science perspective so that we get the acceptability."
"So, we are doing two types of stimulus studies as profile access on the high-risk population for Ashwagandha. We have also planned a competitive study between Hydroxychloroquine and Ashwagandha," he added.
